HCL-GROUP
18.1.2023 12:37:33 CET | Business Wire | Press release
Securing the world’s global freshwater ecosystems, under increasing threat from climate change, population growth and consumer demand, has become more critical than ever. To tackle this escalating crisis, UpLink, the open innovation platform of the World Economic Forum, in partnership with global conglomerate HCL Group, has announced 10 water-focused entrepreneurs who will share CHF1.75 million ($1.9 million) from HCL Group to scale their innovations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005448/en/
Access to water plays a critical role in food production, education, job creation, health and well-being and the preservation of the natural world and is vital to achieving the UN’s 2030 sustainability agenda. However, global demand for water will exceed sustainable supply by 40% by 2030, with huge implications for the global economy and society.
The 10 start-ups are the winners of the Global Freshwater Innovation Challenge, the first of five challenges under HCL and UpLink’s Aquapreneur Innovation Initiative. Launched in September 2022, the challenge called for innovative solutions that would strengthen data-driven decision making, improve freshwater resilience in the face of climate change and restore water quality around the world.
Through a $15 million investment over five years, HCL Group is supporting UpLink and the Forum’s Global Water Initiative to launch a series of innovation challenges and create an innovation ecosystem for the global freshwater sector on UpLink.
The 10 water-focused entrepreneurs, or “aquapreneurs”, were chosen from 227 solutions submitted to the challenge, and will now each receive CHF175,000 ($190,000) in vital funding from HCL Group. Two of these innovators were selected to present their solutions at the World Economic Forum Annual Meeting 2023 in Davos:
- Epic Cleantec, based in the US, is a water technology company leading the water reuse revolution in the urban built environment. Aaron Tartakovsky, CEO of Epic Cleantec, said: “With the combined challenges of ageing infrastructure, growing urban populations and a rapidly changing climate, the conventional approach to how we manage water is no longer sustainable. Epic is on a mission to ensure that our cities are water-secure for generations to come.” Epic aims to use its next-generation technologies to drive circularity in water use and to work with policy-makers to reshape the water infrastructure in cities.
- Kilimo, based in Argentina, uses big data and machine learning to verify, improve, and offset water usage in agriculture. Tatiana Malvasio, Co-Founder and Chief Operating Officer, said: “As founders from Latin America, we have first-hand experience with the tension between agriculture and water stress in our region. In response to this challenge, we set out to create a product that could help farmers reduce their water usage and be more efficient in their irrigation practices.” Kilimo uses artificial intelligence to help farmers optimize irrigation and then be compensated for their participation in water stewardship initiatives.
The other entrepreneurs to be awarded prize money from HCL and support from UpLink are:
- bNovate Technologies (Switzerland) – An automatic, remote biosensor to monitor and detect bacterial concentration in water supplies
- Indra Water (India) – Electrically driven, decentralized wastewater treatment solution with no added chemicals in its primary treatment
- Majik Water Technologies (Kenya) – An atmospheric water generator system that uses proven condensation-based techniques to capture water moisture from the air
- NatureDots Private Limited: AquaNurch (India) – Derisking fisheries and water managers from ecological stressors, enabling remote-control and real-time monitoring of aqua-farms
- Oneka Technologies (Canada) – A wave-powered desalination solution to produce drinking water using renewable energy created through waves
- Openversum (Switzerland) – A locally assembled and managed membrane filter that removes pathogen heavy metals from water
- RainGrid Inc. (Canada) – Building community-scale, property-based, digital networks for net-zero residential property rainfall runoff while generating verifiable ecosystem credits
- Wateroam Pte Ltd (Singapore) – Production of safe, speedy and high-quality drinking water without electricity
“We are delighted to announce the first beneficiaries of the Aquapreneur Innovation Initiative who have been selected after rigorous deliberation among a large panel of experts,” said Roshni Nadar Malhotra, Chairperson, HCLTech. “The availability of fresh water is rapidly changing worldwide, creating a tenuous future requiring attention from policy-makers, the private sector and the public alike. Having witnessed the efforts of aquapreneurs who are finding solutions to challenges around existing freshwater resources, I am positive that we are all moving in the right direction for the future of our planet. Many congratulations to the top 10 awardees.”
“These innovations are crucial to meet the increasing global demand for clean water and support the transition to a greener economy,” said Olivier Schwab, Managing Director, World Economic Forum. “With water scarcity threatening countries all around the world, it’s essential to identify and empower the innovative start-ups that will help secure access to this precious resource, now and for future generations. The Aquapreneur Innovation Initiative, launched by UpLink and HCL, will connect these world-class innovators to the resources, expertise and vital funding they need to scale and drive truly transformational change.”
About UpLink
UpLink is the open innovation platform of the World Economic Forum, designed to unlock an “entrepreneur revolution” for people and planet by supporting start-ups with innovative solutions for the world’s most pressing issues, as outlined by the UN Sustainable Development Goals. Launched at the World Economic Forum Annual Meeting 2020 in Davos in partnership with Deloitte and Salesforce, UpLink builds bridges between entrepreneurs and the investors, experts and partners who can help scale their ventures.
UpLink sources innovations through a competition framework known as innovation challenges. UpLink has run more than 43 challenges and identified over 350 entrepreneurs with innovative solutions across critical SDG areas including health, food, freshwater, ocean, plastics, education, climate and more.
For more information, visit https://uplink.weforum.org
About HCL Group
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the eight-bit microprocessor-based computer in 1978. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies – HCLTech, HCL Infosystems and HCL Healthcare. The group generates annual revenues of over $12.3 billion with more than 222,000 employees operating across 60 countries.
HCLTech, a group company, is among the leading global technology companies. It is delivering cutting-edge capabilities centred around digital, engineering and cloud, powered by a broad portfolio of technology services and products across industry segments. HCLTech is a strategic partner of the World Economic Forum.
For further information, visit www.hcl.com
Notes to editors
About the World Economic Forum Annual Meeting 2023
The World Economic Forum Annual Meeting 2023 will convene the world’s foremost leaders under the theme, Cooperation in a Fragmented World.
Find out more about the Annual Meeting 2023 here
Read the Forum Agenda also in French | Spanish | Mandarin | Japanese
Learn about the Forum’s impact
Check out the Forum’s Strategic Intelligence Platform and Transformation Maps
Follow the Forum on Twitter via @wef@davos | Instagram | LinkedIn | TikTok | Weibo | Podcasts
Become a fan of the Forum on Facebook
Watch Forum videos
Subscribe to Forum news releases and podcasts
The World Economic Forum, committed to improving the state of the world, is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business and other leaders of society to shape global, regional and industry agendas. (www.weforum.org).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005448/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
